Compare AbbVie Inc (ABBV) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Ulta Beauty Inc — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Ulta Beauty Inc trades at $455 (market cap $19.51B). The key difference: AbbVie Inc is far larger — about 23.1× Ulta Beauty Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| ABBV | ULTA | |
|---|---|---|
Market Cap | $449.91B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $706.82 |
52-Week Low | $184.85 | $450.75 |
Enterprise Value | $513.38B | $21.59B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
ULTA Beauty trades at $453.78, down 1.64% recently, with a bearish technical signal from moving averages but oversold RSI near 29. The stock shows strong profitability with a 9.36% net margin and 47.45% ROE, though revenue growth slowed to $11.3B in 2025. Recent news highlights partnerships with Bath & Body Works and AI-driven loyalty initiatives to boost engagement.
Analysts remain bullish with a $623.73 consensus target, citing valuation discounts and market share gains. Risks include competitive pressures and margin compression, but the current P/E of 16.96 offers value if execution improves. The stock presents a contrarian opportunity amid negative sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
